Tuesday, November 17, 2026

Good On Gilead -- Making An Experimental Ebola Therapeutic Available, At Low Cost, Through Dr. Reddy's -- And Others, In Limited Means Geographies...

Well, some in the private sector clearly will not be corrupted by RFK, jr., Trump and Musk. Good on Gilead -- another one of my long time most favored bio-science holdings.

Here are the quite-encouraging details, overnight:

. . .Gilead said on Monday it had signed royalty-free deals with three generic drugmakers ​to make its experimental Ebola prevention drug ‌available in 127 mainly low- and lower-middle-income countries if it succeeds in trials and wins regulatory approvals. . . .

The company has donated more than 38,000 remdesivir vials to the ​Democratic Republic of Congo, Uganda and Kenya, ⁠including more than 2,000 recently sent to Kenya for investigational treatment and post-exposure prevention. Remdesivir is not ⁠approved to treat or prevent Ebola Bundibugyo disease, and its clinical effectiveness has not been established. . . .


Excellent -- more of this, please. Onward.

And in counterpoint, it must be mentioned that RFK, Jr. (and Trump -- for enabling him) have now presided over almost 8,000 US cases of measles -- and 13 fatalities, from measles. In 2026, alone.

A disease we conquered over five decades ago. Deplorable.

नमस्ते

No comments: